MSI 相关指南共识下载
结直肠癌及其他相关实体瘤微卫星不稳定性检测中国专家共识.pdf
ESMO 共识：肿瘤免疫治疗的 MSI 检测及其与 PD-1_PD-L1 表达和 TMB 的关系.pdf
（2020.V1）NCCN 临床实践指南：食道癌和胃食管交界处癌.pdf
（2020.V1）NCCN 临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌.pdf
（2020.V1）NCCN 临床实践指南：肝胆肿瘤.bak.pdf
参考文献：
1. Boland, C.R., et al., A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer. Cancer research, 1997. 58: p. 5248-5257.
2. Umar, A., et al., Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst, 2004. 96(4): p. 261-8.
3. Vilar, E. and S.B. Gruber, Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol, 2010. 7(3): p. 153-62.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer 2019 Version 4. 2019.
5. Dudley, J.C., et al., Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res, 2016. 22(4): p. 813-20.
6. Zheng, J., et al., The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel. Future Oncol, 2018. 14(14): p. 1355-1364.
7. Bai, W., et al., Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. Cancer Med, 2019. 8(5): p. 2157-2166.
8. Christine M. Ribic, M.S., et al., Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. n engl j med 2003. 349(3).
9. Le, D.T., et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med, 2015. 372(26): p. 2509-20.
10. Gryfe, R., et al., Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal Cancer. The New England Journal of Medicine, 2000. 342(2).
11. Popat, S., R. Hubner, and R.S. Houlston, Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 2005. 23(3): p. 609-18.
12. Sargent, D.J., et al., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 2010. 28(20): p. 3219-26.
13. Le, D.T., et al., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017. 357(6349): p. 409-413.
